WHO FAQs on key changes to the treatment of drug-resistant TB
The World Health Organization (WHO) Global TB Program, in close collaboration with the Global Fund to Fight AIDS, Tuberculosis and Malaria, the United States Agency for International Development (USAID) and the Global Drug Facility of the Stop TB Partnership have updated the Frequently Asked Questions (FAQs) document on WHO’s Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis.
These FAQs reinforce the key messages highlighted in the Rapid Communication released in December 2019 and inform national TB programs and other stakeholders about the main steps needed to support rapid transition and planning at the country level.
The updated FAQs are available here.
Source:
WHO
